SUN PHARMA ADVANCED RESEARCH C (SPARC): Financials & Fundamentals History

Share price

Closing priceAdjusted for splits and bonus issues.

3M1Y3YAll

₹210.8 latest close · −11.9% over the last 90 sessions

₹210.8 month-end · +56.7% over 12 months

₹210.8 month-end · −23.3% over 3 years

₹210.8 month-end · +1.0% since Jun '23

52-week range ₹108.00 to ₹289.00 · 1-year volatility 56.8%

How rough has the ride been?

Maximum drawdown-76.1%not yet recovered

1-year volatility56.8%annualised

Beta vs sector index1.343-year daily, correlation 0.39

Volume spikes1last 90 sessions, 5x the 50-day median

Drawdown from peak

Largest drawdowns

-76.1% (2024-04 peak to 2026-03 low, not yet recovered)

-59.4% (2020-02 peak to 2020-03 low, recovered 2021-05)

-52.7% (2022-02 peak to 2023-03 low, recovered 2024-01)

Most recent volume spikes

2026-11-09: 37.8x the 50-day median, price +7.0% that day

Beta is the slope of daily returns against a market-cap-weighted index of the sector's other listed companies, built from today's constituents (so it excludes companies no longer listed).

Where does it rank among Health Technology peers?

Each cell is the company's percentile rank among its Health Technology peers (non-financial companies) that month.
Darker is better-ranked.
Rows marked ↓ are inverted (lower debt, shorter cash cycle and a lower P/E rank higher).

Where it ranks today

ROCE100th▲ 99 pts vs a year ago
Op. margin2ndflat vs a year ago
Revenue growth100th▲ 87 pts vs a year ago
Debt/equity ↓30th
Cash cycle ↓94th▲ 24 pts vs a year ago
P/E ↓99th
12M momentum80th▲ 57 pts vs a year ago

Rank history

ROCE

Op. margin

Revenue growth

Debt/equity ↓

Cash cycle ↓

P/E ↓

12M momentum

Dec '21Jul '22Jan '23Jul '23Jan '24Jul '24Jan '25Jul '25Jan '26Jul '26Nov '26

Lower rank Higher rank Not enough data

Percentiles use today's listed companies in the sector and need at least 5 peers with a value; grey cells have too few.
ROE is computed from net profit and book value where the source does not report it.

The Health Technology sector page Watch it move against Health Technology in the Observatory

What is the price implying?

~25%annual earnings growth implied by the price

At a P/E of 45.6x, the price would imply about 25.2%/yr earnings growth for 10 years under the same assumptions, but it is not ranked.

Fewer than six years of annual earnings are available, which is too little to measure delivered growth.

“Implied growth” is what the current price would require under our stated assumptions, not what we expect.

What prices imply across Health Technology The market-wide Expectations lists

Key figures

Share Priceclose 9 Nov: ₹210.80
P/E: 4.3x
ROCE: 164.0%
Market Cap: ₹6859 cr
Revenue (TTM): ₹1909 cr
P/S: 3.6x
P/B: 5.1x
ROE: 118.7%
Operating Margin: -85.0%
Debt / Equity: 0.4x
Promoter Holding: 65.7%
12M Momentum: 56.7%

52-week range

₹108.00₹289.00

57% of the way from its 52-week low to its high

Price risk

1Y volatility

56.8%

Beta vs sector

1-year daily

1.73

Balance sheet & cash

Interest cover

operating profit ÷ interest

43.8x

Cash from profit, 3Y

operating cash flow ÷ net profit

-1.25x

low

Share count, 1Y

unchanged

Are profits backed by cash?

2 of 6checks within range4 beyond a threshold

Other income reliance1%Within range

Other income as a share of pre-tax profit (trailing twelve months): 0.9%. Bands: below 15%, 15% to 35%, above 35%.

Tax rate0%Beyond threshold

Median quarterly effective tax rate over about 2.5 years: 0.0%. Bands: 15% to 35%, 5% to 15% or 35% to 50%, outside 5% to 50%.

Cash conversion-1.25xBeyond threshold

Operating cash flow divided by net profit over the last three fiscal years: -1.25x (cash from operations ₹-1,028 cr, net profit ₹823 cr). Bands: 0.8x and above, 0.5x to 0.8x, below 0.5x.

Free cash flow0 of 4 yrsBeyond threshold

Fiscal years with positive free cash flow in the last 4: 0. Bands: at least 80% of years, 40% to 80%, below 40%.

Receivable days vs history-73 daysWithin range

Debtor days are below the median of the previous three fiscal years by 73 days (2 vs 75). Bands: under 15 days, 15 to 45, over 45.

Capital work in progress85% of fixed assetsBeyond threshold

Capital work-in-progress is 85% of fixed assets. Bands: not rising or up to 30%; rising for three years and above 30%; rising and above 60%.

Payable days—Not enough data

Not enough reported data to compute this.

Tap a check to see how it is measured

How to read this

Each check is a named rule with fixed thresholds, not a score. Annual statements are the latest restated figures, so a past year may differ from what was originally reported.

All terms explained in the glossary →

Who has been buying and selling?

Over 2 years, FIIs added 0.6 pts; DIIs trimmed 0.6 pts.
The number of shareholders rose from 1.0 lakh to 1.4 lakh (+37%) between Dec 2023 and Jun 2026.

Holdings, Jun '26

How each group changed

GroupDec '23Jun '26Change

Promoters65.7%65.7%0.0 pts

FIIs3.3%3.9%+0.6 pts

DIIs0.7%0.1%-0.6 pts

Public and others30.4%30.3%0.0 pts

Number of shareholders

1.4 lakhshareholders+37% since Dec '23

Quarterly shareholding as reported, labelled by the quarter it covers (it becomes visible about two months later).
Shareholder counts are only available for recent quarters.

This quarter's smart-money board

What happened next to similar setups

−1.3%typical 12-month return vs the marketNot meaningfully different from the base rate

We found 50 past situations where a non-financial company looked like SUN PHARMA ADVANCED RESEARCH C today on valuation, return on capital, margins, debt, growth, price momentum, size and volatility.
Over the following 12 months the middle half of them returned −31% to +24% vs the market, against 0% for all non-financial companies in the same months.
The gap against the base rate (−0.9%, 80% range −16.4% to +9.3%) is within what chance and overlapping periods produce.

Where the 50 outcomes landed

Each dot is one past situation (hover or tap for details) · Solid dots are the closest matches, listed below · Shaded is the middle half of all companies in the same months · 5 beyond the range shown, drawn at the edge

Similar setups' median

−1.3%

All companies' median

−0.4%

Beat the market

48% vs 50%

50 past situations · 50 companies · 28 months · 2020–2025

The closest matches

Company	When	P/E	ROCE	12M mom.	Drawdown	Next 12 months
PVP Technology Services	Apr 2024	5x	61%	+192%	−26%	−24%
IIFLCAPS Finance	Jul 2024	13x	35%	+223%	−7%	+59%
GANESHHOU Finance	Jun 2024	17x	45%	+155%	−9%	+2%
IMAGICAA Consumer Services	Jun 2023	5x	35%	+129%	−15%	+17%
MANALIPETC Process Industries	Jul 2021	7x	49%	+311%	−6%	+18%

Show the other 3 matches

Company	When	P/E	ROCE	12M mom.	Drawdown	Next 12 months
MONARCH Finance	Jun 2024	14x	52%	+114%	−23%	+28%
FACT Process Industries	Dec 2020	4x	27%	+55%	−5%	+59%
DOLATALGO Finance	Jul 2021	14x	64%	+148%	−5%	−46%

How reliable is this?

Matched on P/E, P/S, ROCE, operating margin, debt/equity, interest cover, revenue growth, 12-month momentum, drawdown from 12-month high, size and volatility. Closest on: drawdown from 12-month high, 12-month momentum and volatility. One match per company and at most 7 from any one month.

Independent periods: the matches fall in 6 distinct 12-month windows. Matches from nearby months share the same market conditions, so fewer windows means less evidence.

How this is built

This is history, not a forecast. These are past situations where other companies had broadly similar reported numbers and price trends. What happened to them does not tell you what will happen to SUN PHARMA ADVANCED RESEARCH C. The comparison covers only 2020–2025, a single market period, and only companies still listed today. Companies that were delisted or went bankrupt are missing, which makes past outcomes look better than they were. Returns exclude dividends and are measured against an ApnaFunda-built index, not an official benchmark. Fundamentals are matched on a 60-day assumed reporting lag, not actual announcement dates. Its historical skill has not yet been measured. Past patterns may not repeat.

Methodology

How historical analogs are built

Data as of 2026-11-09. Outcome pool: Jan 2020 to Oct 2025.

For every company we look at the situation it is in today (valuation, return on capital, margins, debt, growth, 12-month price momentum, drawdown, size and volatility) and find past company-months that looked most like it. We then show what happened to those past situations over the following 12 months, measured against the ApnaFunda All index and against the base rate. It describes history. It does not predict anything.

What is compared

Feature	Weight	Non-financial	Financial
P/E	1	yes	yes
P/S	1	yes	—
P/B	1	—	yes
ROCE	1	yes	—
operating margin	1	yes	—
ROE	1	—	yes
debt/equity	0.75	yes	—
interest cover	0.5	yes	—
revenue growth	0.75	yes	yes
12-month momentum	1	yes	yes
drawdown from 12-month high	0.75	yes	yes
size	0.75	yes	yes
volatility	0.5	yes	yes

Weights were set by judgement before any outcome was looked at and are never tuned on results. Loss-making companies (negative P/E or net profit) are only matched with other loss-making companies. Banks, NBFCs and insurers are compared only with each other and use a different feature set. Every feature is converted, month by month, to its rank among companies in the same pool in that month, so a P/E of 30 in a hot market and a P/E of 22 in a cold one can match if both were equally expensive for their time. Only that month's data is used.

How closeness and the sample are defined

Distance is the weighted root-mean-square gap between the standardised features both companies have. A match needs at least 70% of the query's feature weight, a distance of at most 0.9, and 30 matches at minimum to be shown. We keep up to 50 matches with these exclusions: never the company itself, one match per company (its closest month), and at most 7 from any one calendar month so a single market episode cannot dominate.

Base rate

The base rate is the distribution of 12-month returns, relative to the market, of every eligible company-month in the same pool, with each month weighted to match the months the analogs came from. It answers: how did a random company do in these same months? Because matches from nearby months share the same market conditions, we also report the number of distinct 12-month windows behind a result, and a bootstrap that resamples months decides whether the analog median differs from the base rate at all. "Not meaningfully different" is the usual outcome and the page copy is written for it.

Limits you should know

One market period. The outcome pool covers 2020–2025 only (70 months), including the 2020 crash and the 2020–21 rally.
Survivorship. Only companies listed today are included. Delisted and bankrupt companies are missing, which flatters past outcomes, particularly for distressed-looking setups.
Price return only. Dividends are excluded, and the benchmark is an ApnaFunda market-cap-weighted index of the same listed companies, not an official index.
Reporting lag. Fundamentals are matched on an assumed 60-day lag after the quarter end, not on real announcement dates.
Pools: non-financial: 98,395 company-months from 2019 companies; financial: 5,659 company-months from 108 companies. 2349 companies currently have a result; the rest are suppressed because too few comparable situations exist.

Does it work? A walk-forward check

The walk-forward check has not been run for this build, so skill is shown as not yet measured.

Disclaimer

This is history, not a forecast. These are past situations where other companies had broadly similar reported numbers and price trends. What happened to them does not tell you what will happen to any company shown. The comparison covers only 2020–2025, a single market period, and only companies still listed today. Companies that were delisted or went bankrupt are missing, which makes past outcomes look better than they were. Returns exclude dividends and are measured against an ApnaFunda-built index, not an official benchmark. Fundamentals are matched on a 60-day assumed reporting lag, not actual announcement dates. Its historical skill has not yet been measured. Past patterns may not repeat.

What else looks like this?

Companies with the most similar financial profile today, regardless of industry.

ORIANA POWERORIANA

Industrial Services

64%similar

revenue growthrevenue

VIKRAM SOLARVIKRAMSOLR

Process Industries

45%similar

promoter holdingmarket cap

REFEX INDUSTRIESREFEX

Energy Minerals

43%similar

volatilityrevenue

SENCO GOLDSENCO

Consumer Durables

42%similar

promoter holdingmarket cap

SHAKTI PUMPS (INDIA)SHAKTIPUMP

Producer Manufacturing

40%similar

revenue growthdebt/equity

NGL FINE CHEMNGLFINE

Health Technology

12%similar

volatilitydebt/equity

KILITCH DRUGS (I)KILITCH

Health Technology

7%similar

promoter holdingdebt/equity

UNICHEM LABORATORIESUNICHEMLAB

Health Technology

7%similar

revenueP/E

Similarity is statistical, based on reported metrics; it does not imply similar business quality or future returns.

What changed?

30 events since Aug '20

2026
NovPriceVolume reached 37.8x its 50-day median on 2026-11-09; price +7.0% that day.
SepPeer rankSlipped to the bottom quartile of Health Technology on operating margin (from the top quartile).
JunResultsEPS (TTM) turned positive.
JunPeer rankMoved into the top quartile of Health Technology on ROCE (from the bottom quartile).
MayPriceVolume reached 36.0x its 50-day median on 2026-05-25; price +11.1% that day.
MarPriceFell 76% from the Apr 2024 peak to the Mar 2026 low.
MarPriceVolume reached 28.8x its 50-day median on 2026-03-25; price +17.5% that day.
2025
DecPriceVolume reached 553.6x its 50-day median on 2025-12-03; price -5.9% that day.

Show 22 earlier events

2025
JunPriceVolume reached 22.0x its 50-day median on 2025-06-04; price -19.6% that day.
MarPriceVolume reached 45.8x its 50-day median on 2025-03-07; price +8.4% that day.
2024
DecPriceVolume reached 58.0x its 50-day median on 2024-12-16; price +8.8% that day.
AugPriceVolume reached 7.4x its 50-day median on 2024-08-26; price +4.4% that day.
AprPriceVolume reached 66.5x its 50-day median on 2024-04-25; price -5.0% that day.
JanPriceRegained the 2022-02 peak, 10 months after the low.
JanPriceVolume reached 31.9x its 50-day median on 2024-01-03; price +14.4% that day.
2023
NovPriceVolume reached 21.9x its 50-day median on 2023-11-24; price +6.1% that day.
AugPriceVolume reached 33.5x its 50-day median on 2023-08-30; price +8.6% that day.
JunPriceVolume reached 29.4x its 50-day median on 2023-06-26; price +9.1% that day.
MarPriceFell 53% from the Feb 2022 peak to the Mar 2023 low.
MarPriceVolume reached 55.3x its 50-day median on 2023-03-23; price +11.4% that day.
2022
OctPriceVolume reached 11.4x its 50-day median on 2022-10-13; price +3.1% that day.
SepPriceVolume reached 38.8x its 50-day median on 2022-09-29; price +14.9% that day.
JanPriceVolume reached 16.6x its 50-day median on 2022-01-07; price +10.6% that day.
2021
DecPriceVolume reached 9.1x its 50-day median on 2021-12-13; price +8.2% that day.
JulPriceVolume reached 11.3x its 50-day median on 2021-07-30; price +10.6% that day.
MayPriceRegained the 2020-02 peak, 14 months after the low.
MayPriceVolume reached 25.8x its 50-day median on 2021-05-10; price +19.2% that day.
JanPriceVolume reached 10.2x its 50-day median on 2021-01-04; price +3.7% that day.
2020
DecPriceVolume reached 21.4x its 50-day median on 2020-12-31; price +6.7% that day.
AugPriceVolume reached 7.5x its 50-day median on 2020-08-05; price +6.6% that day.

Events are generated from the data by fixed rules.
The month shown is when the change became visible in the reported figures, assuming a 60-day lag after each quarter end; it is not an announcement date.

Where price and fundamentals disagree, market-wide Rewind the whole market to any month

Monthly history42 months · 2023-06 to 2026-11

Month	P/E	Revenue (TTM)	ROE	ROCE	Debt / Equity
2026-11	4.3x	₹1909 cr	118.7%	164.0%	0.4x
2026-10	3.6x	₹1909 cr	118.4%	164.0%	0.4x
2026-09	4.0x	₹1909 cr	118.4%	164.0%	0.4x
2026-08	4.2x	₹1879 cr	116.1%	164.0%	0.4x
2026-07	4.3x	₹1879 cr	116.1%	164.0%	0.4x
2026-06	4.9x	₹1879 cr	116.1%	164.0%	0.4x
2026-05	—	₹53 cr	—	-279.0%	—
2026-04	—	₹53 cr	—	-279.0%	—
2026-03	—	₹53 cr	—	-279.0%	—
2026-02	—	₹60 cr	—	-279.0%	—
2026-01	—	₹60 cr	—	-279.0%	—
2025-12	—	₹60 cr	—	-279.0%	—
2025-11	—	₹65 cr	—	-279.0%	—
2025-10	—	₹65 cr	—	-279.0%	—
2025-09	—	₹65 cr	—	-279.0%	—
2025-08	—	₹72 cr	—	-279.0%	—
2025-07	—	₹72 cr	—	-279.0%	—
2025-06	—	₹72 cr	—	-279.0%	—
2025-05	—	₹62 cr	-311.2%	-108.0%	0.5x
2025-04	—	₹62 cr	-311.2%	-108.0%	0.5x
2025-03	—	₹62 cr	-311.2%	-108.0%	0.5x
2025-02	—	₹61 cr	-327.2%	-108.0%	0.5x
2025-01	—	₹61 cr	-327.2%	-108.0%	0.5x
2024-12	—	₹61 cr	-327.2%	-108.0%	0.5x
2024-11	—	₹69 cr	-310.4%	-108.0%	0.5x
2024-10	—	₹69 cr	-310.4%	-108.0%	0.5x
2024-09	—	₹69 cr	-310.4%	-108.0%	0.5x
2024-08	—	₹76 cr	-309.6%	-108.0%	0.5x
2024-07	—	₹76 cr	-309.6%	-108.0%	0.5x
2024-06	—	₹76 cr	-309.6%	-108.0%	0.5x
2024-05	—	₹239 cr	-43.6%	—	0.0x
2024-04	—	₹239 cr	-43.6%	—	0.0x
2024-03	—	₹239 cr	-43.6%	—	0.0x
2024-02	—	₹239 cr	-43.6%	—	0.0x
2024-01	—	₹239 cr	-43.6%	—	0.0x
2023-12	—	₹239 cr	-43.6%	—	0.0x
2023-11	—	₹239 cr	-43.6%	—	0.0x
2023-10	—	₹239 cr	-43.6%	—	0.0x
2023-09	—	₹239 cr	-43.6%	—	0.0x
2023-08	—	₹239 cr	-43.6%	—	0.0x
2023-07	—	₹239 cr	-43.6%	—	0.0x
2023-06	—	₹239 cr	-43.6%	—	0.0x

Methodology and data notes